The publication of this work is a major milestone for CaroGen, as it provides a peer-reviewed report of our proof-of-concept HBV vaccine studies to date.
Hamden, Conn. (PRWEB) August 17, 2015
CaroGen Corporation, an emerging vaccine company, today announced the electronic publication of a research article entitled “Virus-Like Vesicle-Based Therapeutic Vaccine Vectors for Chronic Hepatitis B Virus Infection,” which appeared in the August online issue of the Journal of Virology.
The paper includes research conducted in the laboratories of Dr. John Rose and Dr. Michael Robek, both faculty at Yale University, with the virus-like vesicle (VLV) platform technology, and the results of preclinical vaccine candidates aimed for treatment of chronic hepatitis B virus (HBV) infection. It is the first publication that includes data from induction of immunogenicity and potential application of VLV-based vaccines using both acute and chronic animal models of HBV.
“The publication of this work is a major milestone for CaroGen, as it provides a peer-reviewed report of our proof-of-concept HBV vaccine studies to date,” said Dr. Bijan Almassian, CEO of CaroGen.
Chronic HBV infection is a condition that affects approximately 240 million individuals globally and causes an estimated 600,000 deaths per year.
“There is a clear need for new therapies for chronically infected individuals,” said Dr. Michael Robek, senior author of the research and faculty member in the department of pathology at Yale University. “With the virus-like vesicle technology and hepatitis B vaccine candidates under development, we are looking to deliver the needed balance of safety combined with induction of functional immune responses.”
The VLV technology was developed by Dr. John Rose, Yale University virologist and professor of pathology at the Yale School of Medicine, and was licensed by CaroGen in 2012.
Connecticut Innovations (CI) has been a key supporter of the company and this work has been received funding through the pre-seed fund and the Connecticut Bioscience Innovation Fund, managed by CI.
CaroGen Corporation is an emerging vaccine company employing a virus-like vesicle (VLV) platform technology developed at Yale University School of Medicine and exclusively licensed for the development and commercialization of vaccines worldwide. The company is developing a portfolio of vaccine candidates with a lead vaccine program in chronic HBV infection – a pathogen of global concern and a leading cause of liver disease and cancer. http://www.carogencorp.com.
Bijan Almassian (203) 230-8596